Goldman Sachs analyst Ziyi Chen upgraded Luye Pharma (LYPHF) to Neutral from Sell with a HK$3.13 price target The firm believes the downside risks have been largely reflected in the stock’s valuation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYPHF: